Listed

Rigel Pharmaceuticals Inc: Form 10-Q for the period ended Sep 30, 2021

Filed with the SEC on Nov 2, 2021 and accepted by EDGAR at Nov 2, 2021, 16:02 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2021-07-01 to 2021-09-30$21.5mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2021-01-01 to 2021-09-30$128.8mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2021-07-01 to 2021-09-30$151.0kus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2021-01-01 to 2021-09-30$596.0kus-gaap:CostOfGoodsAndServicesSold
Selling, general and administrative3 months2021-07-01 to 2021-09-30$22.9mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2021-01-01 to 2021-09-30$67.4mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2021-07-01 to 2021-09-30−$19.8mus-gaap:OperatingIncomeLoss
Operating income9 months2021-01-01 to 2021-09-30$8.9mus-gaap:OperatingIncomeLoss
Interest expense3 months2021-07-01 to 2021-09-30$1.3mus-gaap:InterestExpense
Interest expense9 months2021-01-01 to 2021-09-30$3.6mus-gaap:InterestExpense
Income tax3 months2021-07-01 to 2021-09-30−$136.0kus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2021-01-01 to 2021-09-30$665.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2021-07-01 to 2021-09-30−$21.0mus-gaap:NetIncomeLoss
Net income9 months2021-01-01 to 2021-09-30$4.7mus-gaap:NetIncomeLoss
Diluted EPS3 months2021-07-01 to 2021-09-30−$0.12us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2021-01-01 to 2021-09-30$0.03us-gaap:EarningsPerShareDiluted
Basic EPS3 months2021-07-01 to 2021-09-30−$0.12us-gaap:EarningsPerShareBasic
Basic EPS9 months2021-01-01 to 2021-09-30$0.03us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2021-07-01 to 2021-09-30170,886,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2021-01-01 to 2021-09-30176,452,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2021-01-01 to 2021-09-30$25.0mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2021-01-01 to 2021-09-30$648.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2021-09-30$30.4mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-09-30$171.1mus-gaap:AssetsCurrent
Total assetsAt period end2021-09-30$186.5mus-gaap:Assets
Current liabilitiesAt period end2021-09-30$59.3mus-gaap:LiabilitiesCurrent
Long-term debtAt period end2021-09-30$20.0mus-gaap:LongTermDebt
Shareholders' equityAt period end2021-09-30$49.7mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001558370-21-014076. Last ingested by Listed: Nov 14, 2026, 23:09 ET. Listed shows no prices and gives no investment advice.